Clinical trials for Cervical / Vulvar / Vaginal cancer

Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05581121

[PAROLA] Lymphadénectomie para-aortique dans le cancer du col de l'utérus localement avancé

Cervical cancer Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma Stage III Localized Locally Advanced None Systemic Treatment-Naive Systemic Treatment-Naive

Radiotherapy Radiotherapy

24 recruiting sites

Institut Claudius Regaud

Phase 3 Cervical / Vulvar / Vaginal cancer #NCT03534713

[ONCOCOL01] Chimiothérapie d'induction suivie d'un traitement standard dans le cancer du col de l'utérus avec atteinte des ganglions lymphatiques aortiques

Cervical cancer Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma Stage I Stage II Stage III Stage IV Localized Locally Advanced None Systemic Treatment-Naive Systemic Treatment-Naive

Chemotherapy Chemotherapy

11 recruiting sites

Hôpital universitaire de Toulouse

Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05078047

[MOIO] Étude comparant l'administration standard d'une immunothérapie (IO) vs la même IO administrée tous les 3 mois chez des patients en réponse après 6 mois d'IO standard

Cervical cancer Locally Advanced Metastatic

29 recruiting sites

UNICANCER

Phase 3 Cervical / Vulvar / Vaginal cancer #NCT06459180

[TroFuse-020] Une étude visant à comparer la monothérapie par sacituzumab tirumotecan (MK-2870) au traitement choisi par le médecin comme traitement de deuxième ligne pour les participantes atteintes d'un cancer du col de l'utérus récurrent ou métastatique

Cervical cancer Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma Locally Advanced Metastatic 1 Immunotherapy Immunotherapy Chemotherapy

Systemic Treatment-Naive

6 recruiting sites

Merck Sharp & Dohme LLC

Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06760819 #2024-517419-62-00

[panSOHO] Etude sur l'efficacité du BAY2927088 et sur son innocuité chez les participants atteints d'une tumeur solide présentant des mutations activatices d'HER2

Stomach Oesogastric junction Esophagus Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1

Systemic Treatment-Naive

6 recruiting sites

Bayer

Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT03175224 #2024-514542-37-00

[SPARTA] APL-101 chez des patients atteints de tumeurs solides avancées avec anomalies de MET - Cohortes C, D et F

Locally Advanced Metastatic MET 1 2 3 or more

BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ALK ROS-1 Systemic Treatment-Naive Targeted therapy

5 recruiting sites

Apollomics

Phase 1 / Phase 2 Cervical / Vulvar / Vaginal cancer #NCT06923761 #2023-504845-30-00

[EMITT-1] Essai de ciblage de l'immunopeptidome médié par ERAP - 1

Module 2 (Parties C et D) Cohorte 1 Cancer du col

Cervical cancer Locally Advanced Metastatic 1 2 Immunotherapy

Systemic Treatment-Naive

7 recruiting sites

Grey Wolf Therapeutics

Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT03093116 #2024-512606-25-00

[TRIDENT-1] Étude du REPOTRECTINIB (TPX-0005) chez des patients atteints de tumeurs solides avancées présentant des réarrangements ALK, ROS1 ou NTRK1-3

Groupe 5

Metastatic NTRK-1/2/3 1 2 3 or more Immunotherapy Chemotherapy

Systemic Treatment-Naive Targeted therapy

4 recruiting sites

Turning Point Therapeutics, Inc.

Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT03093116 #2024-512606-25-00

[TRIDENT-1] Étude du REPOTRECTINIB (TPX-0005) chez des patients atteints de tumeurs solides avancées présentant des réarrangements ALK, ROS1 ou NTRK1-3

Groupe 6

Metastatic NTRK-1/2/3 1 2 3 or more Targeted therapy

Systemic Treatment-Naive

4 recruiting sites

Turning Point Therapeutics, Inc.

Phase 1 / Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT04585750 #2023-504251-27-00

[PYNNACLE] Evaluation du PC14586 chez les patients atteints de tumeurs solides avancées hébergeant une mutation TP53 Y220C

Phase 2 autres tumeurs solides

Locally Advanced Metastatic Metastatic Castration-resistant TP53 1 2 3 or more

KRAS G12C KRAS non G12C Systemic Treatment-Naive

9 recruiting sites

PMV Pharmaceuticals, Inc